Anteris Technologies Global Corp. Common Stock

Anteris Technologies announced it has received full regulatory clearance from France's ANSM to conduct the PARADIGM Trial for its DurAVR® Transcatheter Heart Valve. The prospective randomized controlled trial will enroll approximately 1,000 patients to evaluate the safety and effectiveness of DurAVR® compared to commercially available TAVR devi...

Anteris Technologies reported Q1 2026 results with $320 million in capital raises completed to support the PARADIGM Trial for its DurAVR® THV System. The company achieved U.S. patient enrollment commencement post-quarter and secured CMS reimbursement coverage, facilitating U.S. site activation. Net operating cash outflows were $28.7 million, pri...

Anteris Technologies announced it has secured U.S. Medicare reimbursement eligibility for its PARADIGM Trial under a Coverage with Evidence Development model. The trial will evaluate the safety and effectiveness of the company's DurAVR® Transcatheter Heart Valve against commercially available alternatives in approximately 1,000 patients. This mi...

Anteris Technologies reported 2025 financial results with net operating cash outflows of $77.8 million, driven by increased clinical and manufacturing activities. The company initiated the global PARADIGM Trial for its DurAVR® transcatheter heart valve, received FDA IDE approval, and completed a strategic $320 million capital raise including inv...

Anteris Technologies completed a $90 million strategic investment from Medtronic and a $230 million underwritten public offering, totaling $320 million in capital. The funding will support execution of the global PARADIGM trial and advance commercialization of the DurAVR® Transcatheter Heart Valve for treating aortic stenosis.